Brief: Axim says partner Quay Pharma secures permit to continue development of MedChew
02/05/2017 14:09
May 2 (Reuters) - Axim Biotechnologies Inc AXIM.PK
* Axim biotechnologies says partner Quay Pharma obtained
licenses to import, work with controlled drugs required to
continue development of co's MedChew
Source text for Eikon: ID:nGNXNUOZHa
Further company coverage: AXIM.PK
((Bangalore.newsroom@thomsonreuters.com ;))
Recent news on Axim Biotechnologies
See all newsBrief: AXIM Biotechnologies Partners With Arizona State University To Determine Antibody Levels Against Covid-19
Brief: Axim Biotechnologies Inc Develops Next Generation Of Its Rapid Neutralizing Antibody Test For Covid-19
Brief: AXIM Biotechnologies To Acquire Technology Including
Brief: Axim® Biotechnologies Successfully Completes Point-Of-Care Clinical Trials On Its Rapid Covid-19 Neutralizing Antibody Test
Brief: Axim Biotechnologies Inc Says Filed A Provisional Patent For A First-In-Class Face Mask That Captures And Deactivates Sars-Cov-2